Translate Bio Announces Fourth Quarter and Full Year 2018 Financial Results and Reviews Recent Highlights
21 mars 2019 16h29 HE
|
Translate Bio, Inc.
LEXINGTON, Mass., March 21, 2019 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative...
Translate Bio Announces Publication of Preclinical Data Demonstrating Efficacy of Systemic mRNA Delivery in Fabry Disease Model in the Journal Molecular Therapy
18 mars 2019 07h30 HE
|
Translate Bio, Inc.
LEXINGTON, Mass., March 18, 2019 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative...
Translate Bio to Present at the 39th Annual Cowen and Company Healthcare Conference
04 mars 2019 07h30 HE
|
Translate Bio, Inc.
LEXINGTON, Mass., March 04, 2019 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative...
Translate Bio Provides Updates on Cystic Fibrosis (CF) and Ornithine Transcarbamylase (OTC) Deficiency Programs
27 févr. 2019 16h30 HE
|
Translate Bio, Inc.
-- Initiated multiple-ascending dose portion of the Phase 1/2 clinical trial of MRT5005 in patients with cystic fibrosis -- -- Received FDA communication related to previously announced IND clinical...
Translate Bio to Present at the 8th Annual SVB Leerink Partners Global Healthcare Conference
14 févr. 2019 07h30 HE
|
Translate Bio, Inc.
LEXINGTON, Mass., Feb. 14, 2019 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative...
Translate Bio Announces FDA Clinical Hold on Investigational New Drug Application (IND) for MRT5201 for the Treatment of Ornithine Transcarbamylase (OTC) Deficiency
22 janv. 2019 07h30 HE
|
Translate Bio, Inc.
LEXINGTON, Mass., Jan. 22, 2019 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative...
Translate Bio Advances Programs in Cystic Fibrosis (CF) and Ornithine Transcarbamylase (OTC) Deficiency
03 janv. 2019 07h30 HE
|
Translate Bio, Inc.
-- Received approval to begin multiple-ascending dose in Phase 1/2 clinical trial of MRT5005, an mRNA therapeutic for CF -- -- Submitted IND for Phase 1/2 clinical trial of MRT5201, an mRNA...
Translate Bio Appoints Robert Meyer, MD, to its Board of Directors
03 janv. 2019 07h30 HE
|
Translate Bio, Inc.
LEXINGTON, Mass., Jan. 03, 2019 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative...
Translate Bio Expands Patent Portfolio with Newly Issued U.S. Patent Relating to Its Messenger RNA (mRNA) Therapeutics Platform (MRT™)
04 déc. 2018 09h15 HE
|
Translate Bio, Inc.
LEXINGTON, Mass., Dec. 04, 2018 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative...
Translate Bio Announces Third Quarter 2018 Financial Results and Reviews Recent Highlights
08 nov. 2018 16h21 HE
|
Translate Bio, Inc.
Continued progress with ongoing Phase 1/2 clinical trial in CF and towards IND submission for OTC Deficiency LEXINGTON, Mass., Nov. 08, 2018 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a...